ArchiMed closes $1.1bn deal to take Esperion private
PE Hub reported that Esperion shareholders may also receive up to $100 million in contingent payments tied to future net sales.
By Amanda Ross · Deals Correspondent
· 2 min read
ArchiMed has completed a $1.1 billion take-private acquisition of Esperion Therapeutics, the Ann Arbor, Michigan-based biopharmaceutical company, PE Hub reported. The deal moves Esperion from public-market ownership to control by ArchiMed, with shareholders also receiving rights to possible additional payments linked to future commercial performance.
Under the transaction terms reported by PE Hub, Esperion shareholders have the right to participate in contingent milestone payments of as much as $100 million in aggregate. Those payments are tied to future net sales performance, meaning the additional consideration depends on whether agreed sales-related thresholds are met after closing.
Contingent milestone structures are common in healthcare and biopharmaceutical transactions because the value of a business can depend heavily on product adoption, reimbursement, regulatory status and sales execution after a buyer takes control. In this case, PE Hub reported only the aggregate potential amount and the link to future net sales, not the detailed thresholds or timing for any payout.
A take-private transaction generally removes a listed company from the scrutiny and liquidity of public equity markets and places ownership with the buyer and its investors. For shareholders, the structure can combine fixed cash consideration with a contingent value component, allowing sellers to retain some economic exposure to later performance while transferring control of the company at closing.
Esperion was founded in 2008, according to PE Hub. The company is led by chief executive Sheldon Koenig, the report said.
The transaction adds to private-capital activity in healthcare, a sector where investors often evaluate companies against long product cycles and revenue milestones. For biopharmaceutical companies, future net sales can be a central measure of asset performance because they reflect the commercial uptake of approved or marketed therapies after discounts, returns and other deductions defined by the relevant agreements.
PE Hub did not report further financial details in the available material, such as financing sources, shareholder vote results, per-share consideration or any changes to Esperion’s management following the closing. It also did not provide terms governing how the contingent milestone payments would be calculated or distributed beyond the stated aggregate cap and connection to future net sales.
The completed acquisition gives ArchiMed ownership of Esperion at a headline value of $1.1 billion, while leaving former shareholders with a potential, performance-based claim of up to $100 million if the specified sales conditions are achieved.
This story draws on original reporting from PE Hub.
